ctDNA testing in pancreatic cancer and other upper GI malignancies

Suneel Kamath, MD, Cleveland Clinic, Cleveland, OH, discusses emerging evidence in the field of ctDNA in relation to other GI malignancies beyond colorectal cancer. In the domain of pancreatic cancer, early evidence has emerged that a positive ctDNA result after neoadjuvant chemotherapy suggests a patient will be highly likely to recur following surgery. Likewise, in gastric and esophageal cancer, positive ctDNA results after neoadjuvant chemotherapy or chemoradiation may indicate a high likelihood of recurrence even after esophagectomy or gastrectomy. This calls into question the pursual of a potentially dangerous, morbid surgery if the result in the long term is still recurrence. This interview took place at the Great Debates and Updates GI Malignancies Debate in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.